Indication
H3-mutated Glioma
1 clinical trial
2 products
Clinical trial
A MultIceNTER Phase I Peptide VaCcine Trial to Exploit NeoePitope-Specific T Cells for the Treatment of H3-Mutated Gliomas - (INTERCEPT-H3)Status: Recruiting, Estimated PCD: 2025-03-01
Product
TecentriqProduct
H3K27M peptide vaccine